The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.
 
Nabil F. Saba
Honoraria - Bristol-Myers Squibb; Lilly; Merck; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck; Pfizer
Research Funding - Bristol-Myers Squibb; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Pfizer
 
George R. Blumenschein
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Merck
Research Funding - Abbvie (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); GlaxoSmithKline (Inst); immatics (Inst); Kite, a Gilead company (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Xcovery (Inst)
 
Joel Guigay
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Innate Pharma; Merck Serono
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MERCK SERONO (Inst)
 
Lisa F. Licitra
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Eisai; Merck Serono; MSD; Novartis; Roche; SOBI
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Debiopharm Group; Merck Serono; SOBI
 
Jerome Fayette
Leadership - Glycotope GmbH
Honoraria - AstraZeneca; Bristol-Myers Squibb
 
Kevin J. Harrington
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD (Inst); Pfizer (Inst)
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer
Research Funding - AstraZeneca (Inst); MSD (Inst)
 
Naomi Kiyota
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Maura L. Gillison
Consulting or Advisory Role - Aspyerian Therapeutics; AstraZeneca; Bristol-Myers Squibb; Celgene; EMD Serono; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
 
Robert L. Ferris
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Benitec Biopharma; Bristol-Myers Squibb; EMD Serono; Lilly; Merck; Pfizer
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; VentiRx
 
Vijayvel Jayaprakash
Employment - AstraZeneca; Bristol-Myers Squibb; Sanofi (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Mark John Lynch
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Li Li
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Peter Brossart
No Relationships to Disclose